SMI
11.791,91
PKT
-135,20
PKT
-1,13
%
Werbung
Analysen zu SMI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 31.01.12 | ABB (Asea Brown Boveri) halten | Independent Research GmbH | |
| 31.01.12 | Novartis neutral | Goldman Sachs Group Inc. | |
| 31.01.12 | Nestlé outperform | Cheuvreux SA | |
| 31.01.12 | Zurich Insurance buy | Nomura | |
| 31.01.12 | Nestlé overweight | J.P. Morgan Cazenove | |
| 30.01.12 | Novartis kaufen | Hamburger Sparkasse AG (Haspa) | |
| 27.01.12 | UBS underperform | Exane-BNP Paribas SA | |
| 27.01.12 | UBS underperform | Exane-BNP Paribas SA | |
| 27.01.12 | Holcim sell | Citigroup Corp. | |
| 27.01.12 | Logitech neutral | Citigroup Corp. | |
| 27.01.12 | Novartis outperform | Credit Suisse Group | |
| 27.01.12 | Novartis buy | Société Générale Group S.A. (SG) | |
| 26.01.12 | Zurich Insurance halten | Independent Research GmbH | |
| 26.01.12 | Logitech neutral | Sarasin Research | |
| 26.01.12 | Novartis underperform | Cheuvreux SA | |
| 25.01.12 | Holcim neutral | UBS AG | |
| 25.01.12 | Novartis buy | WestLB AG | |
| 25.01.12 | Novartis halten | Independent Research GmbH | |
| 25.01.12 | Novartis buy | Sarasin Research | |
| 25.01.12 | Lonza neutral | Sarasin Research | |
| 24.01.12 | Kühne + Nagel International buy | Citigroup Corp. | |
| 24.01.12 | Novartis buy | Sarasin Research | |
| 24.01.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 23.01.12 | Zurich Insurance neutral | Exane-BNP Paribas SA | |
| 23.01.12 | Novartis buy | Nomura | |
| 20.01.12 | Givaudan reduce | Nomura | |
| 20.01.12 | Novartis buy | Nomura | |
| 20.01.12 | Swiss Re neutral | Nomura | |
| 20.01.12 | Swiss Re hold | Société Générale Group S.A. (SG) | |
| 20.01.12 | Novartis overweight | J.P. Morgan Cazenove | |
| 19.01.12 | Holcim hold | Deutsche Bank AG | |
| 19.01.12 | Swiss Re buy | Sarasin Research | |
| 19.01.12 | ABB (Asea Brown Boveri) verkaufen | National-Bank AG | |
| 19.01.12 | ABB (Asea Brown Boveri) outperform | Sanford C. Bernstein and Co., Inc. | |
| 19.01.12 | UBS overweight | Morgan Stanley | |
| 18.01.12 | Holcim neutral | Exane-BNP Paribas SA | |
| 18.01.12 | UBS underperform | Exane-BNP Paribas SA | |
| 18.01.12 | UBS underperform | Exane-BNP Paribas SA | |
| 18.01.12 | Novartis halten | Independent Research GmbH | |
| 18.01.12 | Novartis hold | Vontobel Research |
* Die angezeigten Realtime Kurse sind indikativ und nicht die offiziellen Börsenkurse. Die Kursdaten können eventuell vom tatsächlichen Marktpreis abweichen.